Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate in Bulk and in Tablet Dosage Form by UV-Spectrophotometry and RP-HPLC
Two methods are described for the simultaneous estimation of Rosuvastatin Calcium and Fenofibrate in binary mixture. The first method was based on UV Spectrophotometric determination of two drugs, using simultaneous equation method. It involves absorbance measurement at 243nm (λmax of Rosuvastatin Calcium) and 287nm (λmax of Fenofibrate) in methanol; linearity was obtained in the range of 1-6 μg/ml and 4-28 μg/ml for Rosuvastatin Calcium and Fenofibrate, respectively. The second method was based on HPLC separation of two drugs in reverse phase mode using Luna C18 column. Linearity was obtained in the concentration of 1-7 μg/ml and 4-28 μg/ml for Rosuvastatin Calcium and Fenofibrate, respectively. Both these methods have been successively applied to pharmaceutical formulation and were validated according to ICH guidelines.
Key words: Rosuvastatin Calcium; Fenofibrate; UV Spectrophotometry; HPLC; Method validation
SJPS 2011; 4(1): 58-63
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.